Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients

被引：18

作者：

Lam J.S. ^{[1
]}

Volpe M.A. ^{[1
]}

Kaplan S.A. ^{[1
]}

机构：

[1] Department of Urology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Avenue, Atchley Pavilion, 11th Floor, New York, 10032, NY

来源：

Current Urology Reports | 2001年 / 2卷 / 4期

关键词：

Benign Prostatic Hyperplasia; Bladder Outlet Obstruction; External Sphincter; Lower Urinary Tract Symptom; Urinary Retention;

D O I：

10.1007/s11934-001-0064-2

中图分类号：

学科分类号：

摘要：

Benign prostatic hyperplasia (BPH) is a frequent disease in men and a major cause of lower urinary tract symptoms (LUTS). Transurethral resection of the prostate (TURP) or open surgery remains the gold standard of treatment for symptomatic BPH. However, 10% to 15% of patients with BPH cannot undergo surgery due to grave concomitant diseases. For patients presenting with contraindications to surgery or anesthesia, several minimally invasive alternative treatment modalities are available. One such therapeutic alternative is prostatic stenting, which can serve as a temporary or permanent solution for bladder outlet obstruction caused by BPH. Although not a new concept, this is a relatively new treatment modality in the United States, primarily because of the strict regulatory forces governing the use of these devices. Prostatic urethral stents have been widely demonstrated to be safe and effective for the treatment of symptomatic BPH. In addition to being minimally invasive, prostatic stenting is generally rapid, easy to perform, immediately effective, and has a low cost compared with conventional surgical treatment. Prostatic stents are therefore well suited to treat the frail elderly patient who would not be able to withstand the stress of undergoing surgery. This report reviews the current use of prostatic urethral stents in the treatment of high-risk surgical patients with BPH. © 2001, Current Science Inc.

引用

页码：277 / 284

页数：7

共 32 条

[1]

Garraway W.M., Collins G.N., Lee R.J., High prevalence of benign prostatic hypertrophy in the community, Lancet, 338, pp. 469-471, (1991)

[2]

Arrighi H.M., Guess H.A., Metter E.J., Et al., Symptoms and signs of prostatism as risk factors for prostatectomy, Prostate, 16, (1990)

[3]

Oesterling J.E., Benign prostatic hyperplasia: Medical and minimally invasive treatment options, N Engl J Med, 332, pp. 99-109, (1995)

[4]

Doll H.A., Black N.A., McPherson K., Et al., Mortality, morbidity, and complications following transurethral resection of the prostate for benign prostatic hypertrophy, J Urol, 147, (1992)

[5]

Roos N.P., Wennberg J.E., Malenka D.J., Et al., Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia, N Engl J Med, 320, pp. 1120-1124, (1989)

[6]

Dotter C.T., Transluminally-placed coilspring endarterial tube grafts: long-term patency in canine popliteal artery, Invest Radiol, 4, (1969)

[7]

Palmaz J.C., Kopp D.T., Hayashi H., Et al., Normal and stenotic renal arteries: experimental balloon-expandable intraluminal stenting, Radiology, 164, (1987)

[8]

Roussequ H., Puel J., Joffre F., Et al., Self-expanding endovascular prosthesis: an experimental study, Radiology, 164, (1987)

[9]

Sigwart U., Puel J., Mirkovitch V., Et al., Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty, N Engl J Med, 316, (1987)

[10]

Wright K.C., Wallace S., Charnsangavej C., Et al., Percutaneous endovascular stents: an experimental evaluation, Radiology, 156, (1985)

← 1 2 3 4 →